RecruitingPhase 2NCT05457465

Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Sponsor

Mclean Hospital

Enrollment

25 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Bipolar Disorder

Summary

Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether cannabidiol (CBD) — a compound from the cannabis plant — can help reduce anxiety and depression in people who have bipolar disorder. Researchers want to see if adding CBD to existing medication is safe and effective. **You may be eligible if...** - You are 18–65 years old - You have a diagnosis of bipolar disorder (type I or II) - You speak and read English fluently - You currently experience at least moderate anxiety - You are on a stable psychiatric medication regimen **You may NOT be eligible if...** - You are currently in a manic or depressive episode - You have a current substance use, eating, or psychotic disorder - You are pregnant or breastfeeding - You currently use cannabis products regularly - You are taking valproate or divalproex - You have a serious neurological condition or allergy to palm oil Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.